Content of the article

SAN FRANCISCO, 02 Feb. Feb. 20, 2022 (GLOBE NEWSWIRE) — Nashville Biosciences, a wholly-owned subsidiary of Vanderbilt University Medical Center (VUMC) that operates BioVU _® , the medical center’s anonymized biobank to support biopharmaceutical research and development, and Datavant, the leader in securely connecting global health data, today announced a collaboration. Collaboration will allow biopharmaceutical companies to connect their trial data to BioVU’s research datasets _® . The links will accelerate drug discovery, clinical development and drug safety activities.

Content of the article

Nashville Biosciences helps life sciences companies answer questions related to drug discovery and health outcomes research by analyzing approximately 3.5 million anonymized electronic medical records, including a subset of approximately 275,000 records related to DNA samples collected through an Institutional Review Board (IRB)-approved process over the past 15 years.

Datavant will extend these capabilities by enabling life science customers to anonymize and compliantly connect their clinical trial and registry data to Nashville Biosciences’ rich clinical, genomic and imaging datasets.

“We are proud of the rich insights we have been able to provide to biopharmaceutical companies searching for new drug targets or striving to understand the natural history of diseases and patient outcomes,” said Leeland Ekstrom, co-founder and director. general. “By working with Datavant, we will be able to go further by enabling the creation of even richer datasets to drive innovation throughout the biopharmaceutical R&D pipeline.”

Content of the article

“Clinico-genomic datasets are essential to unlocking the discovery of new drug targets and improving outcomes research,” said Travis May, Founder and President of Datavant. “Securely connecting this kind of highly nuanced data with clinical trial data will help unlock a sea change in the rate at which new therapies are successfully discovered and brought to market.”

About Nashville Biosciences

Nashville Biosciences, a wholly-owned subsidiary of Vanderbilt University Medical Center (VUMC), was created to harness the medical center’s extensive genomics and bioinformatics resources for drug and diagnostics discovery and development. Leveraging Vanderbilt University Innovation™, Nashville Biosciences serves as the commercial interface between outside companies and the formidable research capabilities represented by BioVU _® , one of the world’s most comprehensive genetic databases linked to anonymized medical records with years of longitudinal clinical data. This unique asset is one of the largest and highest quality of its kind, providing an unprecedented opportunity to guide R&D activity in biotechnology, pharmaceutical, diagnostics, medical devices and other life science applications.

About Datavant

Datavant’s mission is to connect global health data to improve patient outcomes. Datavant strives to reduce the friction of data sharing in the healthcare industry by developing technology that protects patient privacy while supporting the linking of patient health records between datasets. Learn more about Datavant at www.dataavant.com .

Media contacts:

Spencer Andrei
Business Development Manager, Nashville Biosciences
[email protected]

Elenee Argentinis
Marketing Manager at Datavant
[email protected]